Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Ovarian Cancer | Unmet Need | US/EU | 2017

Login to access report north_east
Contact sales account_box

Platinum-based chemotherapy has remained the standard of care for the treatment of platinum-sensitive ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and more recently PARP inhibitors, have entered the therapeutic landscape for this indication. Due to the regulatory approval of targeted therapies, such as Roche/Genentech’s Avastin, AstraZeneca’s Lynparza, Tesaro’s Zejula, and Clovis Oncology’s Rubraca, the market is more crowded leading to higher barriers of entry for emerging therapies in platinum-sensitive ovarian cancer. However, areas of unmet need for the treatment of platinum-sensitive ovarian cancer remain. This content evaluates the key drivers of prescribing and analyzes the areas of significant commercial opportunities that could be valuable commercial opportunities for developers.

Questions Answered:

  • What are the treatment drivers and goals for platinum-sensitive ovarian cancer?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for platinum-sensitive ovarian cancer?
  • What are the prevailing areas of unmet need and opportunity in platinum-sensitive ovarian cancer?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new therapy for platinum-sensitive ovarian cancer?

Markets covered: United States, United Kingdom, France, and Germany.

Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in April 2017.

Key companies: Roche/Genentech, AstraZeneca, Tesaro, Clovis Oncology.

Key drugs: Carboplatin/Paclitaxel, Avastin, Lynparza, Zejula, Rubraca.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…
north_east
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
north_east
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
north_east
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east